90346-06-8 Usage
Uses
Used in Pharmaceutical Industry:
3-Acetylaminomethyl piperidine is used as a key intermediate for the synthesis of various therapeutic drugs. Its presence in the molecular structure of these drugs contributes to their pharmacological properties and efficacy in treating different medical conditions.
Used in Organic Compounds Synthesis:
3-Acetylaminomethyl piperidine is utilized as a building block in the production of a wide range of organic compounds. Its versatile chemical properties allow it to be incorporated into various molecular structures, enhancing the functional groups and reactivity of the resulting compounds.
Used in Drug Development Research:
3-Acetylaminomethyl piperidine plays a significant role in the research and development of new pharmaceutical agents. Its potential applications in drug discovery make it an essential component in the design and synthesis of novel therapeutic agents with improved pharmacological profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 90346-06-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,3,4 and 6 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 90346-06:
(7*9)+(6*0)+(5*3)+(4*4)+(3*6)+(2*0)+(1*6)=118
118 % 10 = 8
So 90346-06-8 is a valid CAS Registry Number.
InChI:InChI=1/C8H16N2O/c1-7(11)10-6-8-3-2-4-9-5-8/h8-9H,2-6H2,1H3,(H,10,11)
90346-06-8Relevant academic research and scientific papers
Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers
Martini, Elisabetta,Ghelardini, Carla,Dei, Silvia,Guandalini, Luca,Manetti, Dina,Melchiorre, Michele,Norcini, Monica,Scapecchi, Serena,Teodori, Elisabetta,Romanelli, Maria Novella
, p. 1431 - 1443 (2008/09/18)
A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity.
